Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporin A in Triple Negative Breast Cancer
NCT06246786Phase 1Withdrawn
- Start
- Jul 2024
- Primary completion
- Jun 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cyclosporine in triple-negative breast cancer (TNBC). Primary endpoint: Ki67 Expression at 6 weeks. Planned start Jul 2024; status: withdrawn.
02
Drugs
cyclosporine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06246786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06246786.